Brigitte Mlineritsch

6.7k total citations
71 papers, 2.9k citations indexed

About

Brigitte Mlineritsch is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Brigitte Mlineritsch has authored 71 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 38 papers in Cancer Research and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Brigitte Mlineritsch's work include Breast Cancer Treatment Studies (31 papers), Cancer Treatment and Pharmacology (24 papers) and Advanced Breast Cancer Therapies (20 papers). Brigitte Mlineritsch is often cited by papers focused on Breast Cancer Treatment Studies (31 papers), Cancer Treatment and Pharmacology (24 papers) and Advanced Breast Cancer Therapies (20 papers). Brigitte Mlineritsch collaborates with scholars based in Austria, United States and Germany. Brigitte Mlineritsch's co-authors include Michael Gnant, R. Jakesz, Richard Greil, W. Kwasny, Christian Menzel, G. Luschin-Ebengreuth, E. Kubista, Michael Seifert, Marianne Schmid and Peter Dubsky and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Brigitte Mlineritsch

69 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brigitte Mlineritsch Austria	25	2.1k	1.2k	843	598	489	71	2.9k
Antonio Frassoldati Italy	27	1.7k 0.8×	876 0.8×	265 0.3×	689 1.2×	705 1.4×	156	2.8k
H. Hausmaninger Austria	21	1.3k 0.6×	910 0.8×	447 0.5×	248 0.4×	568 1.2×	53	2.2k
G. N. Hortobagyi United States	21	1.4k 0.7×	617 0.5×	244 0.3×	465 0.8×	447 0.9×	109	2.1k
José Á. García-Sáenz Spain	29	2.1k 1.0×	1.0k 0.9×	200 0.2×	1.0k 1.7×	631 1.3×	162	3.0k
J. Vinholes United Kingdom	16	2.1k 1.0×	631 0.5×	320 0.4×	1.0k 1.7×	251 0.5×	37	2.6k
Michela Donadio Italy	23	1.1k 0.5×	543 0.5×	166 0.2×	330 0.6×	352 0.7×	68	1.8k
Alan Keller United States	12	1.8k 0.8×	241 0.2×	132 0.2×	665 1.1×	512 1.0×	23	2.4k
Giuseppe Badalamenti Italy	25	1.0k 0.5×	553 0.5×	317 0.4×	764 1.3×	621 1.3×	144	2.3k
Gladys Urbanowitz United States	8	2.0k 1.0×	996 0.9×	134 0.2×	2.2k 3.7×	1.9k 3.9×	12	4.2k
N. Davidson United Kingdom	15	1.3k 0.6×	270 0.2×	130 0.2×	357 0.6×	358 0.7×	41	1.9k

Countries citing papers authored by Brigitte Mlineritsch

Since Specialization

Citations

This map shows the geographic impact of Brigitte Mlineritsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brigitte Mlineritsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brigitte Mlineritsch more than expected).

Fields of papers citing papers by Brigitte Mlineritsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brigitte Mlineritsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brigitte Mlineritsch. The network helps show where Brigitte Mlineritsch may publish in the future.

Co-authorship network of co-authors of Brigitte Mlineritsch

This figure shows the co-authorship network connecting the top 25 collaborators of Brigitte Mlineritsch. A scholar is included among the top collaborators of Brigitte Mlineritsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brigitte Mlineritsch. Brigitte Mlineritsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gnant, Michael, Georg Pfeiler, Günther Steger, et al.. (2019). Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 20(3). 339–351. 152 indexed citations

Rinnerthaler, Gabriel, Simon Peter Gampenrieder, Andreas Petzer, et al.. (2018). Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). BMC Cancer. 18(1). 1074–1074. 12 indexed citations

Mlineritsch, Brigitte, et al.. (2017). ASCO 2017—highlights of gynecological cancer. memo - Magazine of European Medical Oncology. 10(4). 237–239. 4 indexed citations

Gampenrieder, Simon Peter, Clemens Hufnagl, Florian Huemer, et al.. (2016). Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer. The Pharmacogenomics Journal. 17(4). 344–350. 6 indexed citations

Weiß, Lukas, Florian Huemer, Brigitte Mlineritsch, & Richard Greil. (2016). Immune checkpoint blockade in ovarian cancer. memo - Magazine of European Medical Oncology. 9(2). 82–84. 14 indexed citations

Steger, Guenther G., Edgar Petru, Ferdinand Haslbauer, et al.. (2016). Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: a prospective, multicenter non-interventional study. Annals of Oncology. 27. vi74–vi74. 2 indexed citations

Westphal, Theresa, Gabriel Rinnerthaler, & Brigitte Mlineritsch. (2016). Adjuvant medical treatment for breast cancer in elderly and old women. memo - Magazine of European Medical Oncology. 9(1). 17–19. 4 indexed citations

Rinnerthaler, Gabriel, Hubert Hackl, Simon Peter Gampenrieder, et al.. (2015). MiR-16 is the most stable-expressed housekeeping microRNA in breast cancer tissues from primary and metastatic sites. Annals of Oncology. 26. iii10–iii10. 1 indexed citations

Gampenrieder, Simon Peter, Sigrun Ressler, Gabriel Rinnerthaler, et al.. (2014). Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.. PubMed. 34(1). 227–33. 31 indexed citations

10.

Steger, Guenther G., Richard Greil, Alois Lang, et al.. (2013). Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology. 25(2). 366–371. 57 indexed citations

11.

Gnant, Michael, Georg Pfeiler, Herbert Stöger, et al.. (2013). The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. British Journal of Cancer. 109(3). 589–596. 43 indexed citations

12.

Gnant, Michael, Brigitte Mlineritsch, Herbert Stoeger, et al.. (2011). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. The Lancet Oncology. 12(7). 631–641. 335 indexed citations

13.

Mlineritsch, Brigitte, Johannes Andel, Michael Fridrik, et al.. (2009). Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer. Oncology Research and Treatment. 32(1-2). 18–24. 12 indexed citations

14.

Greil, Richard, Martin Moik, Roland Reitsamer, et al.. (2009). Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study. European Journal of Surgical Oncology. 35(10). 1048–1054. 28 indexed citations

15.

Mlineritsch, Brigitte. (2009). Is Higher Efficacy Always at the Price of More Side Effects during Chemotherapy?. Breast Care. 4(3). 162–165. 2 indexed citations

16.

Bartsch, Rupert, Brigitte Mlineritsch, Michael Gnant, et al.. (2008). The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. Breast Cancer Research and Treatment. 115(2). 373–380. 10 indexed citations

17.

Mlineritsch, Brigitte, et al.. (2007). Fulvestrant (‘Faslodex’) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme. Breast Cancer Research and Treatment. 106(1). 105–112. 13 indexed citations

18.

Mlineritsch, Brigitte, et al.. (2004). Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure. Oncology Research and Treatment. 27(5). 441–446. 16 indexed citations

19.

Jakesz, R., H. Hausmaninger, K. Haider, et al.. (1999). Randomized Trial of Low-Dose Chemotherapy Added to Tamoxifen in Patients With Receptor-Positive and Lymph Node–Positive Breast Cancer. Journal of Clinical Oncology. 17(6). 1701–1701. 28 indexed citations

20.

Hausmaninger, H., Heinz Ludwig, Michael Fridrik, et al.. (1995). 5-Fluorouracil and Folinic Acid with or without Alpha-2c Interferon in the Treatment of Metastatic Colorectal Cancer: Preliminary Results of a Multicenter Prospective Randomized Phase-Ill Trial. Oncology Research and Treatment. 18(2). 131–135. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact